Our client is a globally significant, publicly listed pharmaceutical company with deep roots in oncology, and other therapy areas. Ranked among the top 25 global pharmaceutical companies by pipeline size, the organisation has undergone a strategic transformation over the past decade — now with a clear direction and focus.
With over 100 independently developed innovative drug candidates in clinical development,
the European region represents a priority growth market. The organisation currently holds approximately 20 regulatory approvals across the EU, US and Japan, and is executing an ambitious strategy to accelerate the submission, approval, and commercialisation of its innovative pipeline in European markets. This role is critical infrastructure for that ambition.
This is a rare opportunity to build and lead EU regulatory affairs capability for an organisation with the scientific depth of a top-tier global pharma and the urgency ...